| Metric | Value (₹ Cr) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 4.2K | 2.9% | 9.2% |
| Total Income | 4.3K | 2.2% | 11.3% |
| Expenditure | 4.1K | 3.3% | 9.3% |
| PBT | -67.80 | 139.6% | 143.5% |
| Net Profit | -51.80 | 139.0% | 163.9% |
| OPM | 12.94% | 6.23pp | 26.75pp |
| NPM | -1.21% | 4.24pp | 3.31pp |
| EPS | 1.08 | 63.6% | 414.3% |
Biocon Q3FY26 Operating Revenue at Rs 4,173 Cr, Net Profit at Rs 144 Cr
12 Feb 2026 · 12 Feb, 7:53 pm
Summary
Biocon Limited, an innovation-led global biopharmaceuticals company, announced its consolidated financial results for the fiscal third quarter ended December 31, 2025. The company reported an operating revenue of Rs 4,173 crore, a 9% year-on-year growth. The net profit for the quarter was Rs 144 crore. Biocon Biologics and Generics segments reported revenues of Rs 851 crore and Rs 917 crore respectively.
Key Highlights
- 1
Q3FY26 Operating Revenue at Rs 4,173 Cr, up 9% YoY
- 2
Q3FY26 Net Profit at Rs 144 Cr
- 3
Biosimilars revenue at Rs 851 Cr, up 24% YoY
- 4
Generics revenue at Rs 917 Cr, down 3% YoY
- 5
Q3FY26 Core EBITDA at Rs 1,221 Cr, up 21%
- 6
Q3FY26 Core EBITDA Margin at 29%
- 7
Net R&D investments at Rs 249 crore, representing 8% of revenue ex-Syngene
Management Comments
Kiran Mazumdar-Shaw
Chairperson, Biocon Group
This quarter marks the culmination of several strategic steps that have created a stronger and simpler group structure for Biocon Limited. The ~USD 17 billion raised cumulatively through two QIPs within a span of eight months demonstrates robust and sustained investor confidence in our overall business growth and direction.
Siddharth Mittal
CEO & Managing Director, Biocon Limited
The Generics business continued to see momentum in the third quarter, delivering strong sequential and year-on-year revenue growth of 10% and 24%, respectively. This performance was driven by the ongoing launches of gLiraglutide across EU markets, alongside an improved performance in our generic formulations portfolio, supported by select new product launches and base business growth in the U.S.
Shreehas Tambe
CEO & Managing Director, Biocon Biologics Limited
Biocon Biologics reported a robust Q3FY26 performance, with EBITDA of ¥700 crore, up over 44% year on year, driven by strong demand and favorable pricing across key markets. North America continued to power growth during the quarter.
Peter Bains
CEO & Managing Director, Syngene International Limited
The key variable impacting our third quarter performance has been the ongoing impact related to a single product from one of our large molecule biologics clients. Outside of this factor, our underlying business performance has shown steady progress, with the Research Services business continuing to secure new customers and contracts.
Informational and educational content only. Not investment advice.